Cargando…

Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia

PURPOSE: To report the efficacy and safety of lower-sodium oxybate (LXB; Xywav(®)) during the open-label titration and optimization period (OLT) and stable-dose period (SDP) in a clinical study for the treatment of idiopathic hypersomnia. PATIENTS AND METHODS: Data were collected during treatment ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thorpy, Michael J, Arnulf, Isabelle, Foldvary-Schaefer, Nancy, Morse, Anne Marie, Šonka, Karel, Chandler, Patricia, Hickey, Luke, Chen, Abby, Black, Jed, Sterkel, Amanda, Chen, Dan, Bogan, Richard K, Dauvilliers, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618250/ https://www.ncbi.nlm.nih.gov/pubmed/36320423 http://dx.doi.org/10.2147/NSS.S369122

Ejemplares similares

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2020)

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
por: Schneider, Logan D, et al.
Publicado: (2023)

Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy
por: Bogan, Richard K., et al.
Publicado: (2023)

Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia
por: Mignot, Emmanuel, et al.
Publicado: (2023)

O024 Sodium oxybate for refractory narcolepsy and idiopathic hypersomnia: clinical and employment outcomes
por: Hernest, A, et al.
Publicado: (2023)

Idiopathic Hypersomnia—A Dynamic Simulation Model
por: Susta, Marek, et al.
Publicado: (2022)

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023)

Hypersomnia
por: Dauvilliers, Yves, et al.
Publicado: (2005)

The Role of Sodium Oxybate in Idiopathic Hypersomnia: A Case Report Showing Improvement of Excessive Daytime Sleepiness and Reduced Symptoms
por: Vera Ricaurte, Michael, et al.
Publicado: (2023)

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
por: Roth, Thomas, et al.
Publicado: (2022)

Idiopathic Hypersomnia: Historical Account, Critical Review of Current Tests and Criteria, Diagnostic Evaluation in the Absence of Biological Markers and Robust Electrophysiological Diagnostic Criteria
por: Billiard, Michel, et al.
Publicado: (2022)

The Xyrem(®) (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
por: Strunc, Michael J., et al.
Publicado: (2021)

Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
por: Morse, Anne Marie, et al.
Publicado: (2023)

Hypersomnia and depressive symptoms: methodological and clinical aspects
por: Dauvilliers, Yves, et al.
Publicado: (2013)

Symptom Severity and Treatment Satisfaction in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)
por: Schneider, Logan Douglas, et al.
Publicado: (2023)

Impairment in Functioning and Quality of Life in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)
por: Stevens, Joanne, et al.
Publicado: (2023)

[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia
por: Dauvilliers, Yves, et al.
Publicado: (2017)

IgG Abnormality in Narcolepsy and Idiopathic Hypersomnia
por: Tanaka, Susumu, et al.
Publicado: (2010)

Mononucleosis: A Possible Cause of Idiopathic Hypersomnia
por: Sforza, Emilia, et al.
Publicado: (2018)

Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial
por: Bogan, Richard, et al.
Publicado: (2016)

Comparison of the macro and microstructure of sleep in a sample of sleep clinic hypersomnia cases
por: Cairns, Alyssa, et al.
Publicado: (2019)

Kleine-Levin Syndrome and Idiopathic Hypersomnia: Spectrum Disorders
por: Gupta, Ravi, et al.
Publicado: (2011)

Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021)

Stimulating hypocretin receptors improves sleepiness and vigilance in idiopathic hypersomnia: lessons from a proof of concept study
por: Arnulf, Isabelle, et al.
Publicado: (2023)

Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis
por: Bogan, Richard K., et al.
Publicado: (2017)

Manual Characterization of Sleep Spindle Index in Patients with Narcolepsy and Idiopathic Hypersomnia
por: DelRosso, Lourdes M., et al.
Publicado: (2014)

Are unrefreshing naps associated with nocturnal sleep architecture specificities in idiopathic hypersomnia?
por: Mombelli, Samantha, et al.
Publicado: (2023)

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary
por: Rosenberg, Russell, et al.
Publicado: (2023)

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol
por: Thorpy, M, et al.
Publicado: (2021)

Sleep, Narcolepsy, and Sodium Oxybate
por: Mamelak, Mortimer
Publicado: (2022)

Evaluation of the Effect of Modafinil on Cognitive Functions in Patients with Idiopathic Hypersomnia with P300
por: Yaman, Mehmet, et al.
Publicado: (2015)

The melanopsin-mediated pupil response is reduced in idiopathic hypersomnia with long sleep time
por: Rach, Héloïse, et al.
Publicado: (2022)

Idiopathic Hypersomnia Patients Revealed Longer Circadian Period Length in Peripheral Skin Fibroblasts
por: Materna, Linus, et al.
Publicado: (2018)

A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia
por: Miyagawa, Taku, et al.
Publicado: (2022)

Comparing objective wakefulness and vigilance tests to on‐the‐road driving performance in narcolepsy and idiopathic hypersomnia
por: Bijlenga, Denise, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_762vmis6gm6opde44j8pv938rg